Semaglutide improves physical limitations and exercise function in patients of HFpEF with Obesity phenotype regardless of LVEF
Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, shows promise in the treatment of heart failure patients with the obesity phenotype of heart failure with preserved ejection fraction (HFpEF), according to the STEP-HFpEF trial. The study found that semaglutide's benefits in improving symptoms, exercise capacity, and weight were consistent across different left ventricular ejection fraction (LVEF) categories. The results also revealed no safety concerns at any LVEF level. This suggests that semaglutide could be a valuable treatment option for HFpEF patients, regardless of their baseline LVEF.
This study was published in the Journal Of The American College Of Cardiology by Butler J. and colleagues. The STEP-HFpEF trial enrolled 529 patients who had a body mass index of 30 kg/m² or greater and were free from diabetes. Participants had varying LVEFs of 45% or greater and exhibited characteristics associated with HFpEF. They were randomly assigned to receive once-weekly subcutaneous semaglutide 2.4 mg or a placebo in addition to standard care.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.